Regulatory Review
Reviewed by PeptidePrescriber Editorial Team.
Primary sources
The April 15, 2026 FDA update materially changed the category 2 conversation, but it did not erase the difference between a removal notice, a nomination, and final inclusion on the 503A bulks list.
What changed on April 15, 2026
- FDA updated the 503A categories document on April 15, 2026 and issued notice that several peptide-related substances will be removed from category 2 after seven calendar days.
- The update says those removals followed nomination withdrawals. That is different from FDA saying the substances have already been added to the 503A bulks list.
- FDA separately announced a July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting to discuss several peptide-related bulk drug substances for possible inclusion on the 503A bulks list.
What the April update does not mean
The current operational language should stay precise. Removed from category 2 does not itself equal FDA approval, does not itself equal final inclusion on the 503A bulks list, and does not eliminate the need for clinician, counsel, and pharmacy review.
What clinicians should do now
- Use exact date language when discussing regulatory status with patients, staff, and pharmacy partners.
- Do not collapse “removed from category 2” into “FDA-approved” or “finally cleared for routine compounding.”
- Treat the April 2026 change as a live regulatory event that still requires source checking and process review inside your practice.
Primary source language
Use the FDA 503A Categories Update for the current category posture, and the Federal Register meeting notice for the July 23-24, 2026 PCAC agenda and timing.
Starter Pack
Keep regulatory updates aligned with your patient-facing workflow.
Use the starter pack when you want the consent packet, implementation checklist, and regulatory quick reference to stay synchronized with current FDA posture.